JOURNAL OF CANCER RESEARCH AND ONCOBIOLOGY (ISSN:2517-7370)

Biography:

He completed his degree in Medicine and Surgery at the University of Turin.His Current Profession is Assistant Professor, at the University of Turin, Oncology Department. He has many publications in national and international journals. His Research achievements are coordinated a multicenter randomized Phase II clinical trial (Vecti-BIL study) to evaluate the effectiveness of Panitumumab (P) in combination with chemotherapy in patients with advanced BTC selected for the absence of KRAS mutations on exon In preclinical experience, he explored alternative molecules such as ET-743 and the Src inhibitor Saracatinib. He has memberships in American Association of Medical Oncology (ASCO), European Society for Medical Oncology (ESMO), Italian Association of Medical Oncology (AIOM). His previous experience is the coordinator of the activities of the multidisciplinary team for the treatment of digestive cancers at the IRCC Candiolo. Biliary tract cancer (BTC) is a rare and lethal disease with very few therapeutic options. Epithelial Growth Factor Receptor (EGFR) pathway activation could be involved in BTC pathogenesis, envisaging a potential role of anti-EGFR monoclonal antibodies.

Research Interests:

His research interest focuses on new strategies in advanced Bilary cancer treatment.